September 26, 2025 · Form 4 insider transaction
Sandercock Colin bought 30,000 shares of Cue Biopharma, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 70 days after the transaction.
On July 24, 2024 the Reporting Person was granted an option with vesting subject to the satisfaction of performance-based vesting criteria. The performance-based vesting criteria for these shares was deemed satisfied or waived on September 26, 2025 and these shares underlying the option vested.